Curaleaf Holdings Files 6-K, Reports Under Form 40-F

Ticker: CURLF · Form: 6-K · Filed: 2024-08-09T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, reporting, form-40f

TL;DR

Curaleaf filed a 6-K, confirming they use Form 40-F for annual reports.

AI Summary

Curaleaf Holdings, Inc. filed a Form 6-K on August 9, 2024, reporting for the month of August 2024. The filing indicates that Curaleaf will file its annual reports under Form 40-F. The report was signed by Peter Clateman, Chief Legal Officer, on August 8, 2024, and includes a press release as Exhibit 99.1.

Why It Matters

This filing provides an update on Curaleaf's reporting status with the SEC, confirming their use of Form 40-F for annual reports, which is typical for Canadian companies.

Risk Assessment

Risk Level: low — This is a routine administrative filing confirming reporting procedures and does not contain material financial or operational news.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K is to report for the month of August 2024 and to indicate that Curaleaf Holdings, Inc. files its annual reports under cover of Form 40-F.

Who signed this report on behalf of Curaleaf Holdings, Inc.?

Peter Clateman, Chief Legal Officer, signed the report on behalf of Curaleaf Holdings, Inc.

On what date was this report filed with the SEC?

The report was filed as of August 9, 2024.

What is the significance of Curaleaf filing under Form 40-F?

Filing under Form 40-F is a standard procedure for certain foreign private issuers, particularly Canadian companies, to fulfill their annual reporting requirements with the SEC.

What exhibits are included with this filing?

Exhibit 99.1, a Press Release, is included with this filing.

From the Filing

0001756770-24-000059.txt : 20240809 0001756770-24-000059.hdr.sgml : 20240809 20240808173715 ACCESSION NUMBER: 0001756770-24-000059 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240808 FILED AS OF DATE: 20240809 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Curaleaf Holdings, Inc. CENTRAL INDEX KEY: 0001756770 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-249081 FILM NUMBER: 241189798 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 781-451-0117 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: LEAD VENTURES INC. DATE OF NAME CHANGE: 20181023 6-K 1 a6-kcover080824.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number: 333-249081 Curaleaf Holdings, Inc. (Name of Registrant) 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐    Form 40-F ☒ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CURALEAF HOLDINGS, INC. (Registrant) Date: August 8, 2024 By: /s/ Peter Clateman Name: Peter Clateman Title: Chief Legal Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated August 7 , 2024 EX-99.1 2 pressrelease080824.htm EX-99.1 Document Curaleaf Announces CEO Transition Board Appoints Executive Chairman Boris Jordan as Chairman and Chief Executive Officer Outgoing CEO Matt Darin to Retire but Will Stay on as Special Advisor Through Year End STAMFORD, CT, August 7, 2024 – Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf'' or the "Company"), a leading international provider of consumer products in cannabis, today announced that the Board has appointed Executive Chairman Boris Jordan to become Chairman and Chief Executive Officer (CEO) of Curaleaf Holdings, Inc., effective August 16, 2024. Current CEO Matt Darin plans to retire but will stay on as a special advisor through year end to ensure an orderly transition. The announcement was made in conjunction with the Company's quarterly earnings call, during which Curaleaf reported second quarter year-over-year revenue growth of 2% to $342 million, and adjusted EBITDA of $73 million, 21.3% of revenue, with operating and free cash flow from continuing operations of $30 million and $6 million, respectively. Executive Chairman Boris Jordan stated, “Since 2014, it has been a highlight of my career to focus on growing Curaleaf to become the leader of the global cannabis industry as prohibition in the US and around the globe fades. In my role as Chairman and CEO, I have the incredible opportunity to further realize the vision I’ve had for what Curaleaf can ultimately become. As I step into the CEO role to oversee all day-to-day operations, and navigate the strategic direction of the company, I will work tirelessly for our customers, our shareholders, and our team members to ensure the company reaches its fullest potential. While I have remained close to the business as Executive Chairman, in my expanded role as CEO I will be able to effectuate further streamlining of the organization, speed-up decision making, acc

View on Read The Filing